Skip to main content

JDRF has now rebranded to Breakthrough T1D.
Our name has changed, our mission has not.

New JDRF grant will help early career researchers explore fresh ideas in type 1 diabetes

Cardiff University researcher Dr James Pearson is the first recipient of a new JDRF grant designed to test new ideas and expand the horizons of type 1 diabetes research.
Breakthrough T1D profile picture
Kate Gerrard 9 September 2021
James Pearson

Dr James Pearson, recipient of the first JDRF Small Grant Award, is a type 1 diabetes researcher at Cardiff University

Cardiff University researcher Dr James Pearson is the first recipient of a new JDRF grant designed to test new ideas and expand the horizons of type 1 diabetes research.

Dr Pearson will explore whether the time of day affects the immune system’s ability to regulate itself.

This knowledge could change our understanding of how to discover and test new ways to cure or prevent type 1 diabetes.

Dr Pearson’s project will be funded through the new JDRF UK Small Grant Awards programme, which offers researchers up to £15,000 to test out new concepts that might otherwise go unexplored.

A further two projects funded by the programme are due to begin in October 2021, based at the University of Exeter.

Improving our understanding of the immune system

Type 1 diabetes occurs when the immune system mistakenly attacks insulin-producing cells – meaning that its regulatory mechanisms have failed to work as they should.

That is why many researchers are studying how the immune system regulates itself, as a route to discovering treatments that prevent or cure type 1.

However, if the time of day affects how well the immune system can regulate itself, this suggests that a treatment to boost the immune system’s regulation would be more – or less – effective at different times.

Dr Pearson’s work could therefore have significant implications for researchers testing new molecules in the lab for their potential to become new drugs for curing or preventing type 1 diabetes.

It could also affect the way clinical trials of these potential treatments are run, to maximise their chances of success.

Funding to explore new ideas in type 1 diabetes

The JDRF UK Small Grant Awards programme was set up to fill a hole in the type 1 diabetes funding pipeline.

Currently, to secure funding for large-scale projects, researchers first need early data to build a strong case for financial support.

However, as university budgets have become more constrained, it has become increasingly challenging to obtain the funding to generate this early data. Some funders offer one-year grant schemes to support new ideas, but the application processes also require extensive pilot data – creating a vicious cycle.

The Small Grant Awards programme enables UK-based early career researchers to apply for up to £15,000 for short-term pilot projects. Applications are assessed by the JDRF UK Scientific Advisory Council, with support from external reviewers, and JDRF will be closely monitoring if these awards lead to type 1 researchers securing further grants to develop these ideas.

Rachel Connor, Director of Research Partnerships at JDRF in the UK, said: “For years, researchers have reported to us that it is extremely difficult to get funding for small-scale pilot projects that enable them to explore new ideas and concepts. This means that these fresh ideas can often go unexplored for years.

“We believe that the Small Grant Awards programme will help early career researchers to overcome this challenge, meaning that more great ideas from type 1 diabetes researchers are picked up for further support.”

Related news

Read more
Red text 'EASD' blue text '2025' red text 'Vienna'. Ferris wheel in background of logo.
Research
23 September 2025

Six key things to take from this year’s European Association for the Study of Diabetes (EASD) conference

EASD is Europe’s biggest diabetes conference, bringing together experts from around the world to share research and updates that will improve lives, prevent complications, and bring us closer to better treatments. Here are some of the key takeaways that matter most for our community.

Read more
Mother with blonde hair and son with brown hair smiling and hugging taking photograph on smart phone.
Research
19 September 2025

INNODIA trial shows existing drug may slow the progression of type 1 diabetes

A clinical trial called MELD-ATG, run by the clinical trials network INNODIA, has announced positive results at the European Association for the Study of Diabetes (EASD) conference in Vienna this year. It investigated whether a drug called Anti Thymocyte Globulin (ATG) could help preserve insulin producing cells (beta cells)

Read more
ELSA testing kits to screen for type 1 diabetes in children
Research
20 August 2025

Breakthrough T1D takes next step in raising awareness of early detection, with support from Sanofi

We’re pleased to announce that we are launching a new initiative to raise awareness of the importance of early detection in type 1 diabetes (T1D), with support from Sanofi.

Read more
A girl with type 1 diabetes after a teplizumab injection
Research
14 August 2025

MHRA approves licensing for teplizumab to be used in the UK

In a landmark moment, the MHRA has licensed the use of teplizumab in the UK, the first-ever disease-modifying therapy for T1D.